Compare · INCR vs NVO
INCR vs NVO
Side-by-side comparison of Intercure Ltd. (INCR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INCR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 3093.4x INCR ($69.7M).
- Over the past year, INCR is down 31.0% and NVO is down 13.9% - NVO leads by 17.1 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 7 for INCR).
- NVO has more recent analyst coverage (25 ratings vs 1 for INCR).
- Company
- Intercure Ltd.
- Novo Nordisk A/S
- Price
- $5.73-1.88%
- $47.65-2.06%
- Market cap
- $69.7M
- $215.46B
- 1M return
- +16.68%
- -6.48%
- 1Y return
- -30.96%
- -13.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 9
- Recent ratings
- 1
- 25
Intercure Ltd.
InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest INCR
- SEC Form 4 filed by Chief Financial Officer Cohen Amos
- SEC Form 6-K filed by Intercure Ltd.
- InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
- SEC Form D filed by Intercure Ltd.
- InterCure Ltd. Announces 1-for-5 Reverse Share Split
- SEC Form 6-K filed by Intercure Ltd.
- SEC Form 6-K filed by Intercure Ltd.
- Amendment: SEC Form 6-K/A filed by Intercure Ltd.
- SEC Form 6-K filed by Intercure Ltd.
- SEC Form 6-K filed by Intercure Ltd.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S